Imaging how netarsudil eye drops affect the eye's drainage tissue in glaucoma
Tests netarsudil against artificial tears in adults with glaucoma or high eye pressure.
Plain-language title generated from the registry record
Registry title: Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension
Key facts
- Where
- Bloomington, United StatesSee the site
- Phase
- Phase 4
Where in United States
- Indiana Universtiy School of OptometryBloomington, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Indiana University
- Trial code
- NCT07588152
- Record updated
- 11 June 2026
- Original description
This study evaluates the effects of netarsudil (Rhopressa) on the trabecular meshwork in subjects with ocular hypertension or open-angle glaucoma. Participants will be randomized to receive either netarsudil or placebo (artificial tears). High-resolution imaging using adaptive optics gonioscopy, anterior segment optical coherence tomography (AS-OCT), and OCT gonioscopy will be performed at baseline and after approximately 14 days of treatment. The primary objective is to assess changes in trabecular meshwork lamellae spacing, with secondary measures including trabecular meshwork height, width, and Schlemm's canal diameter.Read full original descriptionShow less
Adaptive Optics Gonioscopy In Vivo Imaging of the Effects of Rhopressa on the Trabecular Meshwork in Patients With Ocular Hypertension or Glaucoma
This study evaluates the effects of netarsudil (Rhopressa) on the trabecular meshwork in subjects with ocular hypertension or open-angle glaucoma. Participants will be randomized to receive either netarsudil or placebo (artificial tears). High-resolution imaging using adaptive optics gonioscopy, anterior segment optical coherence tomography (AS-OCT), and OCT gonioscopy will be performed at baseline and after approximately 14 days of treatment. The primary objective is to assess changes in trabecular meshwork lamellae spacing, with secondary measures including trabecular meshwork height, width, and Schlemm's canal diameter.
Inclusion: Adults aged 18 years or older; Diagnosis of ocular hypertension or open-angle glaucoma; Eye examination within the past year; For glaucoma subjects: structural (optic nerve and/or retinal nerve fiber layer) and functional (visual field) findings consistent with glaucoma; Best-corrected visual acuity of 20/100 or better; Open anterior chamber angle as confirmed by gonioscopy and anterior segment optical coherence tomography (AS-OCT); Intraocular pressure between 18 and 34 mmHg (treatment-naïve or after washout, if applicable).
Exclusion: Corneal scarring or active corneal disease that would interfere with imaging; Any condition that, in the opinion of the investigator, would place the subject at increased risk or interfere with study completion; Known intolerance to netarsudil ophthalmic solution; Inability to tolerate gonioscopy procedures; Females of childbearing potential who are not using effective contraception or are not sterile.